Company Profile
Omeros Stock Price, News & Catalysts
- Ticker:
- OMER
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
19.32 USD (+0.26%)
Close
Last updated: August 24, 2026
743M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, OMER closed up 0.26% at $19.32. No new same-company headline was identified in the current news window.
Company overview
Business overview
Omeros is a biotechnology company with programs in immunology, complement biology, and rare disease. The company has long been defined by a mix of scientific ambition and a complicated commercial path.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Omeros sits in specialty biotechnology.
Business Model Characteristics
The business depends on clinical validation, portfolio management, and the ability to unlock value from a narrow set of programs.
Position Within the Biotechnology Landscape
Omeros is a high-uncertainty biotech name whose valuation is driven by pipeline outcomes and strategic progress.
Future catalysts
- Omeros’s catalysts are narsoplimab and the remaining complement / immunology assets. Investors will focus on whether the company can still turn its late-stage biology into something commercially relevant.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Omeros (OMER)?
Omeros (OMER) most recently closed at 19.32 USD, a +0.26% move versus the previous session.
What is the market cap of Omeros (OMER)?
Omeros currently has a market capitalization of 743M USD on BioPharmSignal.
What does Omeros do?
Omeros is a biotechnology company with programs in immunology, complement biology, and rare disease. The company has long been defined by a mix of scientific ambition and a complicated commercial path.
On which exchange is OMER stock listed?
Omeros (OMER) is associated with NASDAQ, United States, Biopharma.
What is narsoplimab?
Omeros’s catalysts are narsoplimab and the remaining complement / immunology assets.
Which conditions is Omeros targeting with narsoplimab?
Omeros is associated with immunology, rare disease based on its company overview and current catalyst commentary.
How does Omeros describe recent progress with narsoplimab?
Omeros’s catalysts are narsoplimab and the remaining complement / immunology assets.
What is Omeros?
Omeros is a biotechnology company with programs in immunology, complement biology, and rare disease.